These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25679193)

  • 1. Biosimilars: from technical to pharmacoeconomic considerations. 30th Rencontres Nationales de Pharmacologie et Recherche clinique pour l'Innovation et l'Evaluation des Technologies de Santé. Tables rondes.
    Girault D; Trouvin JH; Blachier-Poisson C; Gary F; Laloye D; ; Bergmann JF; Casadevall N; Delval C; De Sahb Berkovitch R; Fagon JY; Gersberg M; Lassale C; Lechat P; Le Jeunne C; Montastruc JL; Prugnaud JL; Ratignier-Carbonneil C; Rey-Coquais C;
    Therapie; 2015; 70(1):37-55. PubMed ID: 25679193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars: from Technical to Pharmacoeconomic Considerations.
    Girault D; Trouvin JH; Blachier-Poisson C; Gary F; Laloye D; ; Bergmann JF; Casadevall N; Delval C; De Sahb Berkovitch R; Fagon JY; Gersberg M; Lassale C; Lechat P; Le Jeunne C; Montastruc JL; Prugnaud JL; Ratignier-Carbonneil C; Rey-Coquais C
    Therapie; 2015; 70(1):47-55. PubMed ID: 27393396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarket policy considerations for biosimilar oncology drugs.
    Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
    Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars in psoriasis: what can we expect?
    Radtke MA; Augustin M
    J Dtsch Dermatol Ges; 2014 Apr; 12(4):306-12. PubMed ID: 24698590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biosimilars: assessment of efficacy, safety and cost].
    Domínguez-Gil Hurlé A
    Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Can we transfer the mechanisms of the generics market to biosimilars?].
    Jacke CO; Wild F
    Versicherungsmedizin; 2016 Dec; 68(4):168-72. PubMed ID: 29144113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing oncology biosimilars: an essential approach for the future.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: Hope and concern.
    Emmanouilides CE; Karampola MI; Beredima M
    J Oncol Pharm Pract; 2016 Aug; 22(4):618-24. PubMed ID: 26391898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Economic impact of etanercept and adalimumab biosimilars on hospitals scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products].
    Berreur B; Guerin F; Christophe B; Limido G; Paubel P
    Ann Pharm Fr; 2018 Jan; 76(1):57-63. PubMed ID: 29180236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biosimilars--opportunity or threat?].
    Swierkot J
    Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH; Jacobs IA
    Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Portuguese Society of Rheumatology position paper on the use of biosimilars.
    Fonseca JE; Gonçalves J; Araújo F; Cordeiro I; Teixeira F; Canhão H; da Silva JA; Garcês S; Miranda LC; Ramiro S; Roxo A; Pimentel-Santos FM; Tavares V; Neto A; Sepriano A; Malcata A; Faustino A; Silva C; Ambrósio C; Duarte C; Miguel C; Barcelos F; Santos H; Cunha I; Ramos JC; Gomes JA; Pimentão JB; Costa L; Maurício L; Silva M; Bernardes M; Bogas M; Coelho PC; Monteiro P; Aguiar R; André R; Leitão R; Pimenta S; Meirinhos T; Fernandes S; Las V; Castelão W;
    Acta Reumatol Port; 2014; 39(1):60-71. PubMed ID: 24811463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group.
    de Ridder L; Waterman M; Turner D; Bronsky J; Hauer AC; Dias JA; Strisciuglio C; Ruemmele FM; Levine A; Lionetti P;
    J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):503-8. PubMed ID: 26154031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incentives for market penetration of biosimilars in Belgium and in five European countries.
    Swartenbroekx N; Farfan-Portet ; Espín J; Gerkens S
    J Pharm Belg; 2014 Dec; (4):36-46. PubMed ID: 25562926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biosimilar drugs in oncology].
    Levêque D
    Bull Cancer; 2016 Mar; 103(3):294-8. PubMed ID: 26832422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.